Data Source: Finviz
Hedge Fund Trade Tip (PCN) – Position Completion Notification
Be in the know. 20 key reads for Wednesday…
- Lilly submits authorization request to FDA for antibody-based COVID-19 therapy (MarketWatch)
- Boeing’s Aviation Outlook Is Surprisingly Rosy. What It Means for the Stock. (Barron’s)
- The Labor Department’s Latest Blow Against ESG Investing (Barron’s)
- Trump Pushes for $1,200 Checks, PPP, and Airline Aid After Ending Stimulus Talks (Barron’s)
- House Report Attacks Tech Giants as Monopolists That Stifle Competition (Barron’s)
- What Time Is the 2020 Vice Presidential Debate Tonight? Here When It Starts and What to Watch. (Barron’s)
- Donald Trump’s COVID-19 treatment is similar to the average American hospitalized with coronavirus. Only faster. (USA Today)
- ECB’s Lagarde Pledges No Premature Removal of Monetary Support (Bloomberg)
- Wells Fargo Eliminates More Than 700 Jobs in Commercial Banking (Bloomberg)
- The US economy can survive without new stimulus until after the election and avoid a double-dip recession, Morgan Stanley’s investment chief says (Business Insider)
- Molson Coors (TAP) PT Raised to $62 at Guggenheim, Named ‘Best Idea’ (Street Insider)
- Trump says he’d approve 2nd round of stimulus checks after halting relief talks (Fox Business)
- SEE IT: Bill Murray joins FBN’s ‘The Claman Countdown’ (Fox Business)
- How podcasting became a new front in the streaming wars (Financial Times)
- Bill Gates Says Regulatory Approval For Antibody Drugs Could Sharply Reduce COVID-19 Mortality (Benzinga)
- Real-World Evidence: The Case of Peru (TrialSiteNews)
- Chevron vs. Exxon: Which Is a Better Buy? (U.S. News)
- Global Outlook Brightens as U.S. Consumer Imports Reach Pre-Pandemic Levels (Wall Street Journal)
- Covid-19 Antibody Drug From Glaxo, Vir Enters Final-Stage Testing (Wall Street Journal)
- Hedge funds make pandemic bet on insurance (Reuters)
Tom Hayes – CGTN Global Business Appearance – 10/6/2020
Tom Hayes – The Claman Countdown – Fox Business Appearance – 10/6/2020
Where is money flowing today?
Be in the know. 12 key reads for Tuesday…
- A Prescription for What Ails CVS, Walgreens (Wall Street Journal)
- U.S. Boosts Crude Sales to China, Forcing Saudis to Find Other Markets (Wall Street Journal)
- Prospects for New Round of Stimulus and an Economic Rebound Are Boosting Stocks (Barron’s)
- The Big Banks’ Earnings Are Coming. Here’s What to Expect. (Barron’s)
- China’s Economy Is on the Mend. Here’s Where the Rebound Is Still Uneven. (Barron’s)
- Trump’s Use of Regeneron Antibodies Will Help It Become a Big Seller, Say Analysts (Barron’s)
- Mark Cuban on the ‘best investment’ he ever made: ‘Most people don’t put in the time’ to do it (CNBC)
- Energy companies brace for Hurricane Delta impact, begin rig evacuations (Fox Business)
- ‘The Price Is Right’ returns to production with redesigned set, no audience (Fox Business)
- Peltz, Ackman, Icahn: How Their ‘Hostile’ Reputations Really Work (Institutional Investor)
- Hedge funds seek out emerging markets as Covid-19 continues to wreak havoc (Financial Times)
- U.S. Steps Up Efforts to Counter China’s Dominance of Minerals Key to Electric Cars, Phones (Wall Street Journal)
Unusual Options Activity – Las Vegas Sands Corp. (LVS)
Data Source: barchart
Today some institution/fund purchased 13,026 contracts of March $50 strike calls (or the right to buy 1,302,600 shares of Las Vegas Sands Corp. (LVS) at $50). The open interest was just 2,082 prior to this purchase. Continue reading “Unusual Options Activity – Las Vegas Sands Corp. (LVS)”


